Chugai Pharmaceutical Co., Ltd. (FRA:CUP)

Germany flag Germany · Delayed Price · Currency is EUR
47.55
+2.50 (5.55%)
Last updated: Jan 30, 2026, 3:25 PM CET
22.87%
Market Cap78.99B +14.7%
Revenue (ttm)6.83B +7.5%
Net Income2.36B +12.1%
EPS1.43 +12.1%
Shares Outn/a
PE Ratio33.51
Forward PEn/a
Dividend1.54 (3.23%)
Ex-Dividend DateDec 29, 2025
Volumen/a
Average Volume2
Open47.48
Previous Close45.05
Day's Range47.48 - 47.61
52-Week Range33.02 - 53.18
Betan/a
RSI60.57
Earnings DateJan 29, 2026

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 re... [Read more]

Industry Pharmaceutical Preparations
Founded 1925
Employees 5,026
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol CUP
Full Company Profile

Financial Performance

In 2025, Chugai Pharmaceutical's revenue was 1.26 trillion, an increase of 7.46% compared to the previous year's 1.17 trillion. Earnings were 434.01 billion, an increase of 12.06%.

Financial numbers in JPY Financial Statements